Karyopharm Therapeutics (NASDAQ:KPTI) Cut to Hold at StockNews.com

StockNews.com cut shares of Karyopharm Therapeutics (NASDAQ:KPTI) from a buy rating to a hold rating in a report released on Wednesday.

Several other brokerages also recently commented on KPTI. Piper Sandler lifted their target price on Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a report on Wednesday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $3.00 target price on shares of Karyopharm Therapeutics in a report on Wednesday, August 7th. Robert W. Baird cut their target price on Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Karyopharm Therapeutics in a report on Friday, November 1st. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $5.00.

Karyopharm Therapeutics Price Performance

KPTI stock traded up $0.02 during midday trading on Wednesday, reaching $0.91. 230,098 shares of the stock were exchanged, compared to its average volume of 1,263,632. The stock has a market capitalization of $112.97 million, a PE ratio of -0.75 and a beta of 0.16. Karyopharm Therapeutics has a 52 week low of $0.62 and a 52 week high of $1.95. The company has a fifty day moving average price of $0.81 and a 200 day moving average price of $0.91.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Tuesday, November 5th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.01. The company had revenue of $38.78 million for the quarter, compared to analyst estimates of $37.86 million. During the same period in the previous year, the firm posted ($0.30) earnings per share. As a group, analysts anticipate that Karyopharm Therapeutics will post -0.95 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. AQR Capital Management LLC lifted its stake in shares of Karyopharm Therapeutics by 494.5% in the 2nd quarter. AQR Capital Management LLC now owns 748,020 shares of the company’s stock valued at $649,000 after purchasing an additional 622,194 shares during the period. Cubist Systematic Strategies LLC acquired a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at about $494,000. Acadian Asset Management LLC acquired a new position in Karyopharm Therapeutics during the 2nd quarter worth approximately $167,000. Point72 DIFC Ltd acquired a new position in Karyopharm Therapeutics during the 2nd quarter worth approximately $31,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Karyopharm Therapeutics during the 2nd quarter worth approximately $143,000. 66.44% of the stock is owned by institutional investors and hedge funds.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).